Recent clinical investigations highlight the promising role of sulodexide, an LMW GAG that is actually a mixture of two GAGs—HS and dermatan sulfate (DS)—in ameliorating proteinuria in DN patients, even when co-administered with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor antagonists, suggesting its potential for renal protection [203,204]. The gene discussed is ACE; the disease is liver dysplastic nodule.